Dr Reddy’s
Stay updated with the latest news and articles about Dr Reddy’s.
Latest Articles
UBS initiates Sell call on Zydus, Dr Reddy’s, Aurobindo Pharma, Lupin
UBS has initiated sell ratings on key Indian pharmaceutical stocks including Zydus, Dr. Reddy's, Aurobindo, and Lupin, citing overestimated core margins and slow growth in their primary markets of India and the US.
Dr. Reddy’s refutes Congress allegations over engagement with Dhaval Buch’s Agora Advisory
Dr. Reddy’s clarified that it engaged Agora Advisory for a limited period from October 2020 to April 2021, specifically for leadership coaching services provided by Mr. Dhaval Buch.
Dr Reddy’s signs non-exclusive patent licensing agreement with Takeda Pharma for Vonoprazan tablets in India
Dr. Reddy’s today announced that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited ("Takeda") to commercialise Vonoprazan tablets in India.
Sensex gains more than 200 Points, while the Nifty trades over 17,200
The benchmarks for Indian equities opened higher on Monday, continuing their fourth straight session of gains.
India to accept 1-Dose Sputnik Light Trial Data from Russia
The makers of the first shot of Russian-made Sputnik V vaccine, Sputnik Light says that it demonstrated an efficacy of 79.4 per cent.
Delay in commercial launch of Sputnik V, says Dr Reddy
Russia would import the first 50 million jabs ensuring a speedier rollout before the Indian pharmaceuticals company’s start producing the Sputnik V vaccines.
Dr Reddy’s relaunches over-the-counter Famotidine Tablets in the US market
In October 2017, Dr Reddy's had recalled 569,000 store-brand famotidine tablets in the U.S. due to failed tests for impurities and degradation and it was its second recall of the same medication since July 2016.
Showing 30 of 591,210 articles